NCT03558932

Unknown

IP3R Modulation by Cancer Genes in Mesothelioma

KU Leuven Source

Other study identifiers

Sponsor study identifier

IP3mesov1

Study Type

observational

Estimated enrollment

20

Locations

0 countries

Sites

N/A

Timeline

Study Start

January 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

December 2023

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

June 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 20 participants
Study completion date: June 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 0 countries · 0 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
May 23, 2018
Actual (reported)
First Posted
June 15, 2018
Actual (reported)
Study Start
January 2019
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
December 2023
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
June 2024
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: June 15, 2018
Status Verified: June 2018
Last Update Submitted: June 5, 2018

Conditions

Malignant Mesothelioma

Outcome Measures

Primary Outcomes (1)

Pleural biopsy
Biopsy
5 years

Other Outcomes (3)

Immunoblotting
5 years
Cytometric analysis (FACS-based approaches)
5 years
Live cell imaging for Ca2+-signaling
5 years

Interventions

pleural biopsyDiagnostic test

diagnostic sampling

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 89 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

mesothelioma

You may qualify if:

suspicion of mesothelioma

Sponsors & Collaborators

KU Leuven
Otherlead

Biospecimen

Retention: SAMPLES WITHOUT DNA

pleural biopsies

MeSH Terms

Conditions

Mesothelioma, Malignant

Condition Hierarchy (Ancestors)

MesotheliomaAdenomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsNeoplasms, MesothelialLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SitePleural NeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

Jonas Yserbyt
Catholic university Leuven
PRINCIPAL INVESTIGATOR

Central Study Contacts

Jonas Yserbyt

CONTACT

+32 16 34 68 01 jonas.yserbyt@uzleuven.be

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

May 23, 2018

First Posted

June 15, 2018

Study Start

January 2019

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

December 2023

NCT00898547

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Terminated

NCT00075699

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma

Phase 3Completed

NCT00513877

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Phase 2Completed

NCT02519049

11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)

Completed

NCT00003508

Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma

Phase 2Terminated

NCT01649024

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Phase 2Unknown

referral for diagnostic thoracoscopy

You may not qualify if:

contra-indication for thoracoscopy

Contact the study team to confirm eligibility.

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

June 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

June 15, 2018

Record last verified: 2018-06

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03558932
Data provider: ClinicalTrials.gov
Source updated: 2018-06-15
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:38:22 UTC

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Other Outcomes (3)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record